… non-small-cell lung cancer (NSCLC). Skin rash and diarrhea are well-known and common
adverse events in patients receiving erlotinib, … of erlotinib in patients with NSCLC cancers. …

… Based on a literature search, we identified randomized controlled trials of first-line therapy
for advanced non-small cell lung cancer. The impact of absolute difference in objective …

… factor receptor (EGFR) non-small cell lung cancers, but most patients develop drug resistance.
This … To highlight one study testing celecoxib and erlotinib, of 17 patients in which EGFR …

… aspect of the treatment of non-small-cell lung carcinoma (NSCLC)… Wang et al. found that
celecoxib (a selective inhibitor of … Similarly, the combined effect of erlotinib and pertuzumab was …

… erlotinib monotherapy for pretreated elderly patients with advanced EGFR wild-type nonsmall
cell lung … and vinorelbine for patients in stage IIIB-IV non-small cell lung cancer: a phase II …

… Although this study included a time period preceding the publication of the value frameworks,
a recent study evaluated RCT outcomes in breast, colorectal, and non-small-cell lung …

… as non-small-cell lung cancer (NSCLC)70, small-cell lung cancer71 and chemotherapy-naive …
-1 inhibitor, in patients with stage IIIB/IV non-small cell lung cancer who had relapsed after, …

… in unresectable stage III non-small cell lung cancer: a … gefitinib in previously treated
advanced non-small-cell lung … erlotinib for patients with advanced stage non-small-cell lung …

… with OS in patients with colorectal cancer (CRC) and non-small cell lung cancer (NSCLC).
In … controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR …